Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
about
In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian CancerOlaparib in the management of ovarian cancerAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsMinireview: Regulatory T Cells and Ovarian Cancer.Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series.Approaches to identifying synthetic lethal interactions in cancer.The promise and challenge of ovarian cancer models.Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.Pharmacodynamic study of (131)I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer.Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.Advantages of the avian model for human ovarian cancerNausea as a sentinel symptom for cytotoxic chemotherapy effects on the gut-brain axis among women receiving treatment for recurrent ovarian cancer: an exploratory analysis.RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer ModelsMetronomic Chemotherapy: Seems Prowess to Battle against Cancer in Current ScenarioThe Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis.HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity StudiesMethyl pyruvate protects a normal lung fibroblast cell line from irinotecan-induced cell death: Potential use as adjunctive to chemotherapy.Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.Conditioned media from human ovarian cancer endothelial progenitor cells induces ovarian cancer cell migration by activating epithelial-to-mesenchymal transition.Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication.Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.Exenatide modulates tumor-endothelial cell interactions in human ovarian cancer cells.Studies of lncRNAs in DNA double strand break repair: what is new?Clinical significance and biological role of Wnt10a in ovarian cancer.A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POLθ pathways.Immunotherapy for ovarian cancer: what are the targets of the future?Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin.Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models.Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon betaTranscriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival
P2860
Q26742109-679B8122-55A9-4092-8A36-713E28B55B17Q26797166-DF9CFE97-B7F8-4F9F-ADC7-28C95B365A27Q26798674-0D0E84D1-0BB0-40DA-85D3-E94075011E45Q30244214-2B58095F-B513-4039-B052-8F603CA7D8E5Q33858199-A473D109-789E-4E4E-935C-9A55CC8DB5BEQ35647469-9AE17A86-D313-4217-A4D9-45B1DFE32465Q35771750-DB670408-E54F-4624-AA73-7D52D77FE577Q35780059-06BAAEDD-C4AB-42D3-9ED2-A56286E9FB61Q35820674-526BEF97-8DB3-46C6-9D23-DAAECA7AED87Q35870549-B3D842AA-3D4C-41C4-A80B-416083BF921BQ36085104-DEE13DA2-66F9-4C61-B647-3BBC6E85874FQ36334681-3336670E-FBB3-481A-B12E-3CA03D66927AQ36840009-90AA97E0-D57C-4312-A9FE-88A1730E71B3Q37137877-51BD1F62-EE4C-452D-BF83-C306E74CE76DQ37447340-1D739F51-11A2-4E3E-864E-E762919DA02AQ37543011-4C67EDE5-0D28-45E0-A1F1-FE01C5BF013AQ37631697-9F5FEC06-0E58-419A-9E6F-955E40150CD3Q37661852-9032CDE5-A9F1-48AD-ADDA-7582E6855C6BQ38639870-F36EF839-5287-45A0-BCD3-D9487DB77AD7Q38695207-608B6A01-A8AC-4449-BE42-F63C061BDE26Q38706490-03590910-837E-4D36-A1B0-1961DD5C685FQ38825709-F4C503DC-AE0D-4778-8BCE-6EDD1A2C7ADCQ38883131-65EB4209-6235-453C-9748-943E947F559EQ39174042-3CCB59FF-596F-4F23-958D-1CE63E12AE55Q41016807-9079973B-4E40-4FBF-B19A-314AB5E30B7DQ42378380-F8D9D428-3B09-458E-810A-B8DAEEBE822FQ44197738-93A55B1A-E6AA-426D-853A-0E7FB43B3B52Q46237274-6357C3B7-4BE1-4FD6-830B-13EB76385D09Q47134956-E5ED103F-4CCD-4CDB-93A0-013EC01D254CQ47861842-682C92C8-9929-4FBA-B770-77E5E358A1D4Q48243360-EB4EC1DC-CD91-4AAF-BB2C-FDAFFF12555FQ48489326-43882F94-CE14-4B42-8729-E55D3CD8C7F0Q50664932-3253A3D7-7BA9-49E7-BB5A-4B60E9BDC0ACQ52596252-FDAD28AA-2D3D-4001-A9A0-594F6F553401Q52598486-7A6BD0F1-5A72-4E3E-980E-EE2A1E8DBC82Q55282202-A9235493-DE9C-4DF2-8585-978231096A52Q58711564-A53FE35C-6133-4810-BC9A-5188F4525A51Q58738631-19E9CCFF-F0D2-43EF-9A32-84AEE44FDD1A
P2860
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@ast
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@en
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@nl
type
label
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@ast
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@en
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@nl
prefLabel
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@ast
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@en
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@nl
P2093
P2860
P3181
P356
P1476
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.
@en
P2093
P2860
P304
P3181
P356
10.1177/1758834014544121
P577
2014-09-01T00:00:00Z